New strategies for targeting and treatment of multi-drug resistant Staphylococcus aureus

Acebrón, 2015, The allosteric site for the nascent cell wall in Penicillin-Binding Protein 2a: an achilles’ heel of methicillin-resistant Staphylococcus aureus, Curr. Med. Chem., 22, 1678, 10.2174/0929867322666150311150215 Amoroso, 2012, A peptidoglycan fragment triggers β-lactam resistance in Bacillus lichenformis, PLoS Pathog., 8, e1002571, 10.1371/journal.ppat.1002571 Arguelles Arias, 2013, Characterization of amylolysin, a novel lantibiotic from Bacillus amyloliquefaciens GA1, PLoS One, 8, e83037, 10.1371/journal.pone.0083037 Arya, 2013, An insight into pleiotropic regulators Agr and Sar: molecular probes paving the new way for antivirulent therapy, Future Microbiol., 8, 1339, 10.2217/fmb.13.92 Balaban, 2000, Prevention of diseases caused by Staphylococcus aureus using the peptide RIP, Peptides, 21, 1301, 10.1016/S0196-9781(00)00272-2 Baldry, 2016, The agr inhibitors solonamide B and analogues alter immune responses to Staphylococccus aureus but do not exhibit adverse effects on immune cell functions, PLoS One, 11, e0145618, 10.1371/journal.pone.0145618 Balemans, 2010, Essentiality of FASII pathway for Staphylococcus aureus, Nature, 463, E3, 10.1038/nature08667 Barbosa, 2015, Class I and class II lanthipeptides produced by Bacillus spp, J. Natural Prod., 78, 2850, 10.1021/np500424y Bassetti, 2014, Eravacycline for the treatment of intra-abdominal infections, Expert Opin. Investig. Drugs, 23, 1575, 10.1517/13543784.2014.965253 Bassetti, 2015, Development of novel antibacterial drugs to combat multiple resistant organisms, Langenbecks Arch. Surg., 400, 153, 10.1007/s00423-015-1280-4 Bettiol, 2015, Challenges and solutions for clinical development of new antibacterial agents: results of a survey among pharmaceutical industry professionals, Antimicrob. Agents Chemother., 59, 3695, 10.1128/AAC.00638-15 Bhagwat, 2006, The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase, Antimicrob. Agents Chemother., 50, 3568, 10.1128/AAC.00641-06 Biedenbach, 2012, Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia, Int. J. Antimicrob. Agents, 39, 321, 10.1016/j.ijantimicag.2011.11.016 Bierbaum, 1985, Induction of autolysis of staphylococci by the basic peptide antibiotics Pep 5 and nisin and their influence on the activity of autolytic enzymes, Arch. Microbiol., 141, 249, 10.1007/BF00408067 Bosse, 2005, Internalization of bacteria by osteoblasts in a patient with recurrent, long-term osteomyelitis. A case report, J. Bone Joint Surg. Am., 87, 1343, 10.2106/00004623-200506000-00022 Boucher, 2014, Once-weekly dalbavancin versus daily conventional therapy for skin infection, N. Engl. J. Med., 370, 2169, 10.1056/NEJMoa1310480 Bouley, 2015, Discovery of antibiotic (E)‑3-(3-carboxyphenyl)-2-(4-cyanostyryl)quinazolin-4(3H)‑one, J. Am. Chem. Soc., 137, 1738, 10.1021/jacs.5b00056 Brackman, 2016, The quorum sensing inhibitor hamamelitannin increases antibiotic susceptibility of Staphylococcus aureus biofilms by affecting peptidoglycan biosynthesis and eDNA release, Sci. Rep., 6, 20321, 10.1038/srep20321 Breukink, 2006, Lipid II as a target for antibiotics, Nat. Rev. Drug Discov., 5, 321, 10.1038/nrd2004 Brincat, 2012, Ligand promiscuity between the efflux pumps human p-glycoprotein and S. aureus NorA, ACS Med. Chem. Lett., 3, 248, 10.1021/ml200293c Brown, 2015, Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?, Nat. Rev. Drug Discov., 14, 821, 10.1038/nrd4675 Bubeck Wardenburg, 2007, Surface proteins and exotoxins are required for the pathogenesis of Staphylococcus aureus pneumonia, Infect. Immun., 75, 1040, 10.1128/IAI.01313-06 Cameron, 2016, Vancomycin susceptibility in methicillin-resistant Staphylococcus aureus is mediated by YycHI activation of the WalRK essential two-component regulatory system, Sci. Rep., 6, 30823, 10.1038/srep30823 Campbell, 2011, Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosyntheses in Staphylococcus aureus, ACS Chem. Biol., 6, 106, 10.1021/cb100269f Carter, 2000, Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics, Nature, 407, 340, 10.1038/35030019 Chait, 2007, Antibiotic interactions that select against resistance, Nature, 446, 668, 10.1038/nature05685 Chang, 2010, Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis, Clin. Ther., 32, 454, 10.1016/j.clinthera.2010.03.013 Chen, 2016, Small-molecule targeting of a diapophytoene desaturase inhibits S. aureus virulence, Nat. Chem. Biol., 12, 174, 10.1038/nchembio.2003 Clauditz, 2006, Staphyloxanthin plays a role in the fitness of Staphylococcus aureus and its ability to cope with oxidative stress, Infect. Immun., 74, 4950, 10.1128/IAI.00204-06 Coates, 2014 Cobrado, 2012, Cerium, chitosan and hamamelitannin as novel biofilm inhibitors?, J. Antimicrob. Chemother., 67, 1159, 10.1093/jac/dks007 Contreras-Martel, 2011, Structure-guided design of cell wall biosynthesis inhibitors that overcome β-lactam resistance in Staphylococcus aureus (MRSA), ACS Chem. Biol., 6, 943, 10.1021/cb2001846 Corey, 2014, Single-dose oritavancin in the treatment of acute bacterial skin infections, N. Engl. J. Med., 370, 2180, 10.1056/NEJMoa1310422 Crompton, 1988, The inhibition of serine β-lactamases by specific boronic acids, Biochem. J., 251, 453, 10.1042/bj2510453 Czaplewski, 2016, Alternatives to antibiotics −- a pipeline portfolio review, Lancet, 16, 239, 10.1016/S1473-3099(15)00466-1 D'Elia, 2006, Wall teichoic acid polymers are dispensable for cell viability in Bacillus subtilis, J. Bacteriol., 188, 8313, 10.1128/JB.01336-06 D'Elia, 2006, Lesions in teichoic acid biosynthesis in Staphylococcus aureus lead to a lethal gain of function in the otherwise dispensable pathway, J. Bacteriol., 188, 4183, 10.1128/JB.00197-06 D'Elia, 2009, Probing teichoic acid genetics with bioactive molecules reveals new interactions among diverse processes in bacterial cell wall biogenesis, Chem. Biol., 16, 548, 10.1016/j.chembiol.2009.04.009 de Jonge, 1993, Abnormal peptidoglycan produced in a methicillin-resistant strain of Staphylococcus aureus grown in the presence of methicillin: functional role for penicillin-binding protein 2A in cell wall synthesis, Antimicrob. Agents Chemother., 37, 342, 10.1128/AAC.37.2.342 de Lencastre, 1994, Molecular aspects of methicillin resistance in Staphylococcus aureus, J. Antimicrob. Chemother., 33, 7, 10.1093/jac/33.1.7 DeLeo, 2009, Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era, J. Clin. Invest., 119, 2464, 10.1172/JCI38226 Diekema, 2001, Clin. Infect. Dis., 32, S114, 10.1086/320184 Doroshenko, 2014, Extracellular DNA impedes the transport of vancomycin in Staphylococcus epidermidis biofilms preexposed to subinhibitory concentrations of vancomycin, Antimicrob. Agents Chemother., 58, 7273, 10.1128/AAC.03132-14 Drawz, 2010, Three decades of β-lactamase inhibitors, Clin. Microbiol. Rev., 23, 160, 10.1128/CMR.00037-09 Duggal, 2007, Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up, BMC Ear Nose Throat Disord., 7, 5, 10.1186/1472-6815-7-5 Duscha, 2014, Identification and evaluation of improved 4′-O-(Alkyl) 4,5-disubstituted 2-deoxystreptamines as next-generation aminoglycoside antibiotics, MBio, 5, 10.1128/mBio.01827-14 Eyal, 2016, A novel peluromutilin antibacterial compound, its binding mode and selectivity mechanism, Sci. Rep., 6, 39004, 10.1038/srep39004 Fischer, 2014, GdpS contributes to Staphylococcus aureus biofilm formation by regulation of eDNA release, Int. J. Med. Microbiol., 304, 284, 10.1016/j.ijmm.2013.10.010 Foletti, 2013, Mechanism of action and in vivo efficacy of a human-derived antibody against Staphylococcus aureus α-hemolysin, J. Mol. Biol., 425, 1641, 10.1016/j.jmb.2013.02.008 Fontaine, 2014, First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump, J. Med. Chem., 57, 2536, 10.1021/jm401808n Forge, 2000, Aminoglycoside antibiotics, Audio Neurootol., 5, 3, 10.1159/000013861 Foster, 2014, Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus, Nat. Rev. Microbiol., 12, 49, 10.1038/nrmicro3161 Fox, 2006, Successful therapy of experimental endocarditis caused by vancomycin-resistant Staphylococcus aureus with a combination of vancomycin and beta-lactam antibiotics, Antimicrob. Agents Chemother., 50, 2951, 10.1128/AAC.00232-06 Frère, 1976, Occurrence of a serine residue in the penicillin-binding site of the exocellular DD-carboxy-peptidase-transpeptidase from Streptomyces R61, FEBS Lett., 70, 257, 10.1016/0014-5793(76)80770-3 Frère, 2016, From An enzyme able to destroy penicillin to carbapenemases: 70 years of beta-lactamase misbehaviour, Curr. Drug Targets, 17, 974, 10.2174/1389450116666151001112859 Francis, 2005, Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes, Clin. Infect. Dis., 40, 100, 10.1086/427148 Fuchs, 2011, Entianin, a novel subtilin-Like lantibiotic from Bacillus subtilis subsp. spizizenii DSM 15029T with high antimicrobial activity, App. Environ. Microbiol., 77, 1698, 10.1128/AEM.01962-10 Fuda, 2005, β-lactam resistance in Staphylococcus aureus: the adaptive resistance of a plastic genome, Cell. Mol. Life Sci., 62, 2617, 10.1007/s00018-005-5148-6 Götz, 2002, Staphylococcus and biofilms, Mol. Microbiol., 43, 1367, 10.1046/j.1365-2958.2002.02827.x Garzoni, 2011, Return of the Trojan horse: intracellular phenotype switching and immune evasion by Staphylococcus aureus, EMBO Mol. Med., 3, 115, 10.1002/emmm.201100123 Ge, 1999, In vitro antibacterial properties of pexiganan, an analog of magainin, Antimicrob. Agents Chemother., 43, 782, 10.1128/AAC.43.4.782 Gentry, 2007, Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin, Antimicrob. Agents Chemother., 51, 2048, 10.1128/AAC.01066-06 Ghuysen, 1994, Molecular structures of penicillin-binding proteins and β-lactamases, Trends Microbiol., 2, 372, 10.1016/0966-842X(94)90614-9 Giacometti, 2005, RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis, Peptides, 26, 169, 10.1016/j.peptides.2004.09.018 Goffin, 1998, Multimodular penicillin-binding proteins: an enigmatic family of orthologs and paralogs, Microbiol. Mol. Biol. Rev., 62, 1079, 10.1128/MMBR.62.4.1079-1093.1998 Gottler, 2009, Structure, membrane orientation, mechanism, and function of pexiganan–a highly potent antimicrobial peptide designed from magainin, Biochym. Biophys. Acta, 1788, 1680, 10.1016/j.bbamem.2008.10.009 Gov, 2001, RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: structure and function analysis, Peptides, 22, 1609, 10.1016/S0196-9781(01)00496-X Greenlee-Wacker, 2014, Phagocytosis of Staphylococcus aureus by human neutrophils prevents macrophage efferocytosis and induces programmed necrosis, J. Immunol., 192, 4709, 10.4049/jimmunol.1302692 Gresham, 2000, Survival of Staphylococcus aureus inside neutrophils contributes to infection, J. Immunol., 164, 3713, 10.4049/jimmunol.164.7.3713 Hackbarth, 1993, blaI and blaR1 regulate β-lactamase and PBP2a production in methicillin- resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 37, 1144, 10.1128/AAC.37.5.1144 Halimi, 2010, Antilisterial activity on poultry meat of amylolysin, a bacteriocin from Bacillus amyloliquefaciens GA1, Probiotics Antimicrob Proteins, 2, 120, 10.1007/s12602-010-9040-9 Hamad, 2010, The antibiotics market, Nat. Rev. Drug Discov., 9, 675, 10.1038/nrd3267 Hidayat, 2006, High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity, Arch. Intern. Med., 166, 2138, 10.1001/archinte.166.19.2138 Hiramatsu, 2001, The emergence and evolution of methicillin-resistant Staphylococcus aureus, Trends Microbiol., 9, 486, 10.1016/S0966-842X(01)02175-8 Hua, 2015, MEDI4893 promotes survival and extends the antibiotic treatment window in a Staphylococcus aureus immunocompromised pneumonia model, Antimicrob. Agents Chemother., 59, 4526, 10.1128/AAC.00510-15 Huber, 2009, Chemical genetic identification of peptidoglycan inhibitors potentiating carabapenem activity against methiciliin-resistant Staphylococcus aureus, Chem. Biol., 16, 837, 10.1016/j.chembiol.2009.05.012 Inoshima, 2011, A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice, Nat. Med., 17, 1310, 10.1038/nm.2451 Iscla, 2015, A new antibiotic with potent activity targets MscL, J. Antibiotics, 68, 453, 10.1038/ja.2015.4 Jang, 2016, Multidrug efflux pumps in Staphylococcus aureus and their clinical implications, J. Microbiol., 54, 1, 10.1007/s12275-016-5159-z König, 1995, Effects of Staphylococcus aureus leukocidins on inflammatory mediator release from human granulocytes, J. Infect. Dis., 171, 607, 10.1093/infdis/171.3.607 Kaatz, 1991, Mechanisms of fluoroquinolone resistance in Staphylococcus aureus, J. Infect. Dis., 163, 1080, 10.1093/infdis/163.5.1080 Kaatz, 2005, Effect of promoter region mutations and MgrA overexpression on transcription of norA, which encodes a Staphylococcus aureus multidrug efflux transporter, Antimicrob. Agents Chemother., 49, 161, 10.1128/AAC.49.1.161-169.2005 Kalia, 2012, Capsaicin, a novel inhibitor of the NorA efflux pump, reduces the intracellular invasion of Staphylococcus aureus, J. Antimicrob. Chemother., 67, 2401, 10.1093/jac/dks232 Karginov, 2007, Inhibition of S. aureus alpha-hemolysin and B. anthracis lethal toxin by beta-cyclodextrin derivatives, Bioorg. Med. Chem., 15, 5424, 10.1016/j.bmc.2007.05.058 Katayama, 2016, Complete reconstitution of the vancomycin-intermediate Staphylococcus aureus phenotype of strain Mu50 in vancomycin-susceptible S. aureus, Antimicrob. Agents Chemother., 60, 3730, 10.1128/AAC.00420-16 Kavanagh, 1951, Antibiotic substances from basidiomycetes: VIII. pleurotus multilus (Fr.) sacc. and pleurotus passeckerianus pilat, PNAS, 37, 570, 10.1073/pnas.37.9.570 Kiedrowski, 2011, New approaches for treating staphylococcal biofilm infections, Ann. N. Y. Acad. Sci., 1241, 104, 10.1111/j.1749-6632.2011.06281.x Kiran, 2008, Discovery of a quorum-sensing inhibitor of drug-resistant Staphylococcal infections by structure-based virtual screening, Mol. Pharmacol., 73, 1578, 10.1124/mol.107.044164 Kloss, 1999, Resistance mutations in 23S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center, J. Mol. Biol., 294, 93, 10.1006/jmbi.1999.3247 Kobayashi, 2010, Rapid neutrophil destruction following phagocytosis of Staphylococcus aureus, J. Innate Immun., 2, 560, 10.1159/000317134 Kong, 2016, Targeting Staphylococcus aureus toxins: a potential form of anti-virulence therapy, Toxins (Basel), 8, E72, 10.3390/toxins8030072 Koning, 2012, Interventions for impetigo, Cochrane Database Syst. Rev., 1, 10.1002/14651858.CD003261.pub3 Kumar, 2013, New drugs for methicillin-resistant Staphylococcus aureus: an update, J. Antimicrob. Chemother., 68, 1465, 10.1093/jac/dkt045 Lee, 2010, Development of improved inhibitors of wall teichoic acid biosynthesis with potent activity against Staphylococcus aureus, Bioorg. Med. Chem. Lett., 20, 1767, 10.1016/j.bmcl.2010.01.036 Lehar, 2015, Novel antibody-antibiotic conugate eliminates intracellular S. aureus, Nature, 527, 323, 10.1038/nature16057 Lim, 2002, Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus, Nat. Struct. Biol., 9, 870 Ling, 2015, A new antibiotic kills pathogens without detectable resistance, Nature, 517, 455, 10.1038/nature14098 Liu, 2009, Structure of a tetrameric MscL in an expanded intermediate state, Nature, 461, 120, 10.1038/nature08277 Locke, 2009, Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700), Antimicrob. Agents Chemother., 53, 5265, 10.1128/AAC.00871-09 Lovering, 2012, Structural insights into the anti-methicillin-resistant Staphylococcus aureus (MRSA) activity of ceftobiprole, J. Biol. Chem., 287, 32096, 10.1074/jbc.M112.355644 Lowy, 1998, Staphylococcus aureus infections, N. Engl. J. Med., 339, 520, 10.1056/NEJM199808203390806 Lyon, 2004, Peptide signaling in Staphylococcus aureus and other Gram-positive bacteria, Peptides, 25, 1389, 10.1016/j.peptides.2003.11.026 Münch, 2014, The lantibiotic NAI-107 binds to bactoprenol-bound cell wall precursors and impairs membrane functions, J. Biol. Chem., 289, 12063, 10.1074/jbc.M113.537449 Matt, 2010, The ribosomal A-site: decoding, drug target, and disease, Isr. J. Chem., 50, 60, 10.1002/ijch.201000003 Matteï, 2010, Bridging cell wall biosynthesis and bacterial morphogenesis, Curr. Opin. Struct. Biol., 20, 749, 10.1016/j.sbi.2010.09.014 McCormick, 2009, Chemical inhibition of alpha-toxin, a key corneal virulence factor of Staphylococcus aureus, Invest Opthalmol. Vis. Sci., 50, 2848, 10.1167/iovs.08-3157 Mendes, 2008, First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States, Antimicrob. Agents Chemother., 52, 2244, 10.1128/AAC.00231-08 Mendes, 2014, Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms, Drug Resist. Updat., 17, 1, 10.1016/j.drup.2014.04.002 Mendo, 2004, Purification and characterization of a new peptide antibiotic produced by a thermotolerant Bacillus licheniformis strain, Biotechnol. Lett., 26, 115, 10.1023/B:BILE.0000012888.72489.3f Mensa, 2014, Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16, Antimicr. Agents Chemother., 58, 5136, 10.1128/AAC.02955-14 Miles, 2002, Subunit composition of a bicomponent toxin: staphylococcal leukocidin forms an octameric transmembrane pore, Protein Sci., 11, 894, 10.1110/ps.4360102 Nannini, 2010, Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus, Curr. Opin. Pharmacol., 10, 516, 10.1016/j.coph.2010.06.006 Neyfakh, 1993, Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter, Antimicrob. Agents Chemother., 37, 128, 10.1128/AAC.37.1.128 Nielsen, 2014, Solonamide B inhibits quorum sensing and reduces Staphylococcus aureus mediated killing of human neutrophils, PLoS One, 9, e84992, 10.1371/journal.pone.0084992 Nikolaidis, 2014, Resistance to antibiotics targeted to the bacterial cell wall, Protein Sci., 23, 243, 10.1002/pro.2414 O'Daniel, 2014, Discovery of a new class of non-β-lactam inhibitors of penicillin-binding proteins with Gram-positive antibacterial activity, J. Am. Chem. Soc., 136, 3664, 10.1021/ja500053x Ortega, 2016, New insights into the biosynthetic logic of ribosomally synthesized and post-translationally modified peptide natural products, Cell Chem. Biol., 23, 31, 10.1016/j.chembiol.2015.11.012 Park, 2006, In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone, Antimicrob. Agents Chemother., 50, 2261, 10.1128/AAC.01407-05 Park, 2010, DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae, Int. J. Antimicrob. Agents, 36, 97, 10.1016/j.ijantimicag.2010.02.022 Perichon, 2006, Synergism between beta-lactams and glycopeptides against VanA-type methicillin-resistant Staphylococcus aureus and heterologous expression of the vanA operon, Antimicrob. Agents Chemother., 50, 3622, 10.1128/AAC.00410-06 Perichon, 2009, VanA-type vancomycin-resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 53, 4580, 10.1128/AAC.00346-09 Peschel, 2006, The co-evolution of host cationic antimicrobial peptides and microbial resistance, Nat. Rev. Microbiol., 4, 529, 10.1038/nrmicro1441 Pfister, 2003, The molecular basis for A-site mutations conferring aminoglycoside resistance: relationship between ribosomal susceptibility and X-ray crystal structures, Chembiochem, 4, 1078, 10.1002/cbic.200300657 Phelan, 2013, Subtilomycin: a new lantibiotic from Bacillus subtilis strain MMA7 isolated from the marine sponge Haliclona simulans, Mar Drugs, 11, 1878, 10.3390/md11061878 Pinho, 2001, Complementation of the essential peptidoglycan transpeptidase function of Penicillin-Binding Protein 2 (PBP2) by the drug resistance protein PBP2a in Staphylococcus aureus, J. Bacteriol., 183, 6525, 10.1128/JB.183.22.6525-6531.2001 Putty, 2011, Characterization of d-boroAla as a novel broad-spectrum antibacterial agent targeting d-Ala-d-Ala ligase, Chem. Biol. Drug Des., 78, 757, 10.1111/j.1747-0285.2011.01210.x Qiu, 2012, Capsaicin protects mice from Community-Associated Methicillin-Resistant Staphylococcus aureus pneumonia, PLoS One, 7, e33032, 10.1371/journal.pone.0033032 Que, 2005, Fibrinogen and fibronectin binding cooperate for valve infection and invasion in Staphylococcus aureus experimental endocarditis, J. Exp. Med., 201, 1627, 10.1084/jem.20050125 Queenan, 2007, Interactions of ceftobiprole with beta-lactamases from molecular classes A to D, Antimicrob. Agents Chemother., 51, 3089, 10.1128/AAC.00218-07 Ragle, 2009, Anti alpha-hemolysis monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia, Infect. Immun., 77, 2712, 10.1128/IAI.00115-09 Ragle, 2010, Prevention and treatment of Staphylococcus aureus pneumonia with a β-cyclodextrin derivative, Antimicrob. Agents Chemother., 54, 298, 10.1128/AAC.00973-09 Recht, 1999, Basis for prokaryotic specificity of action of aminoglycoside antibiotics, EMBO J., 18, 3133, 10.1093/emboj/18.11.3133 Renwick, 2016, International and European initiatives targeting innovation in antibiotic drug discovery and development Roberts, 2005, Update on acquired tetracycline resistance genes, FEMS Microbiol. Lett., 245, 195, 10.1016/j.femsle.2005.02.034 Rouha, 2015, Five birds, one stone: neutralization of α-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody, MAbs, 7, 243, 10.4161/19420862.2014.985132 Rouzic, 2010, Prompt and successful toxin-targeting treatment of three patients with necrotizing pneumonia due to Staphylococcus aureus strains carrying the Panton-Valentine leukocidin genes, J. Clin. Microbiol., 48, 1952, 10.1128/JCM.01892-09 Ruiz, 2014, Analysis of structure and hemolytic activity relationships of antimicrobial peptides (AMPs), vol. 232, 253 Sandiford, 2015, Perspectives on lantibiotic discovery −- where have we failed and what improvements are required?, Expert Opin. Drug Discov., 10, 315, 10.1517/17460441.2015.1016496 Saravolatz, 2015, Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus, Clin. Infect. Dis., 52, 1156, 10.1093/cid/cir147 Schindler, 2013, Inhibition of drug efflux pumps in Staphylococcus aureus: current status of potentiating existing antibiotics, Future Microbiol., 8, 491, 10.2217/fmb.13.16 Schindler, 2015, Analyses of multidrug efflux pump-like proteins encoded on the Staphylococcus aureus chromosome, Antimicrob. Agents Chemother., 59, 747, 10.1128/AAC.04678-14 Scully, 2014, Covering all the bases: preclinical development of an effective Staphylococcus aureus vaccine, Front. Immunol., 5, 109, 10.3389/fimmu.2014.00109 Shenkarev, 2010, Isolation, structure elucidation, and synergistic antibacterial activity of a novel two-component lantibiotic lichenicidin from Bacillus licheniformis VK21, Biochemistry, 49, 6462, 10.1021/bi100871b Sieradzki, 1999, Inactivated PBP4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus, J. Biol. Chem., 274, 18942, 10.1074/jbc.274.27.18942 Sievert, 2008, Vancomycin-resistant Staphylococcus aureus in the United States, 2002–2006, Clin. Infect. Dis., 46, 668, 10.1086/527392 Song, 1996, Structure of staphylococcal alpha-hemolysin, a heptameric transmembrane pore, Science, 274, 1859, 10.1126/science.274.5294.1859 Spink, 2015, Structure-activity relationship for the oxadiazole class of antibiotics, J. Med. Chem., 58, 1380, 10.1021/jm501661f Sutcliffe, 2013, Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens, Antimicrob. Agents Chemother., 57, 5548, 10.1128/AAC.01288-13 Suzuki, 2011, In vitro antimicrobial activity of wall teichoic acid biosynthesis inhibitors against Staphylococcus aureus isolates, Antimicrob. Agents Chemother., 55, 767, 10.1128/AAC.00879-10 Swoboda, 2009, Discovery of a small molecule that blocks wall teichoic acid biosynthesis in Staphylococcus aureus, ACS Chem. Biol., 4, 875, 10.1021/cb900151k Tan, 2012, Restoring methicillin-resistant Staphylococcus aureus susceptibility to b-lactam antibiotics, Sci. Transl. Med., 4, 10.1126/scitranslmed.3003592 Tkaczyk, 2012, Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency, Clin. Vacc. Immun., 19, 377, 10.1128/CVI.05589-11 Truong-Bolduc, 2003, Characterization of NorR protein, a multifunctional regulator of NorA expression in Staphylococcus aureus, J. Bacteriol., 147, 305 Turk, 2011, New noncovalent inhibitors of Penicillin-Binding Proteins from penicillin-resistant bacteria, PLoS One, 6, e19418, 10.1371/journal.pone.0019418 Urbina, 2013, Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections, Drug Des. Devel. Ther., 7, 243 Vollmer, 2010, Architecture of peptidoglycan: more data and more models, Trends Microbiol., 18, 59, 10.1016/j.tim.2009.12.004 Vollmer, 2008, Peptidoglycan structure and architecture, FEMS Microbiol. Rev., 32, 149, 10.1111/j.1574-6976.2007.00094.x von Eiff, 2005, Infections associated with medical devices: pathogenesis, management and prophylaxis, Drugs, 65, 179, 10.2165/00003495-200565020-00003 Vuong, 2016, Investigational drugs to treat methicillin-resistant Staphylococcus aureus, Expert Opin. Investig. Drugs, 25, 73, 10.1517/13543784.2016.1109077 Walsh, 2002, The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus, Ann. Rev. Microbiol., 56, 657, 10.1146/annurev.micro.56.012302.160806 Walsh, 2003, Where will new antibiotics come from?, Nat. Rev. Microbiol., 1, 65, 10.1038/nrmicro727 Walton, 2015, MscL: channeling membrane tension, Pflugers Arch., 467, 15, 10.1007/s00424-014-1535-x Wang, 2013, Discovery of wall teichoic acid inhibitors as potential anti-MRSA β-lactam combination agents, Chem. Biol., 20, 272, 10.1016/j.chembiol.2012.11.013 Weidenmaier, 2008, Teichoic acids and related cell wall glycopolymers in Gram-positive physiology and host interactions, Nat. Rev. Microbiol., 6, 276, 10.1038/nrmicro1861 White, 2004, Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent, J. Antimicrob. Chemother., 53, i3, 10.1093/jac/dkh050 Zasloff, 2002, Antimicrobial peptides of multicellular organisms, Nature, 415, 389, 10.1038/415389a Zhanel, 2012, Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin, Expert Rev. Anti-Infect Ther., 10, 459, 10.1586/eri.12.25 Zhanel, 2016, Review of eravacycline, a novel fluorocycline antibacterial agent, Drugs, 76, 567, 10.1007/s40265-016-0545-8 Zhang, 2010, Efflux pump inhibitors: a strategy to combat p-glycoprotein and the NorA multidrug resistance pump, ChemMedChem, 5, 811, 10.1002/cmdc.201000006 Zipperer, 2016, Human commensals producing a novel antibiotic impair pathogen colonization, Nature, 535, 511, 10.1038/nature18634